Table 4.

Determination of RDV and MFX in pharmaceutical preparations and co-formulated dosage form by the proposed methods

Method	Remdesivir-Eva 100 mg/vial		Moxiflox 400 mg/tablet		Co-formulated dosage form
					RDV		MFX
	Conc. (µg/mL)	% R *	Conc. (µg/mL)	% R *	Conc. (µg/mL)	% R *	Conc. (µg/mL)	% R *
Ratio derivative	1	100.77	4	98.06	1	99.48	4	99.13
	1.5	99.18	6	99.01	1.5	101.77	6	99.54
	2	98.38	8	98.41	2	100.97	8	100.62
	2.5	101.53	10	98.22	2.5	99.46	10	98.11
	Mean	99.97	Mean	98.43	Mean	100.42	Mean	99.35
	%RSD	1.144	%RSD	0.422	%RSD	1.142	%RSD	1.046
Ratio difference	1	100.72	4	101.87	1	100.08	4	101.70
	1.5	98.40	6	100.47	1.5	98.11	6	100.43
	2	100.30	8	101.16	2	99.66	8	99.73
	2.5	101.52	10	101.93	2.5	101.01	10	101.38
	Mean	100.23	Mean	101.36	Mean	99.72	Mean	100.81
	%RSD	1.323	%RSD	0.681	%RSD	1.213	%RSD	0.893
Mean centering	1	99.93	4	99.29	1	98.18	4	100.28
	1.5	98.67	6	100.25	1.5	99.25	6	98.18
	2	101.33	8	99.70	2	99.90	8	98.96
	2.5	100.82	10	99.13	2.5	98.45	10	99.32
	Mean	100.19	Mean	99.59	Mean	98.94	Mean	99.19
	%RSD	1.162	%RSD	0.501	%RSD	0.793	%RSD	0.877
Area under the curve	1	101.80	4	98.14	1	101.57	4	98.10
	1.5	98.76	6	98.47	1.5	99.60	6	98.26
	2	101.87	8	99.33	2	100.61	8	99.33
	2.5	98.16	10	98.29	2.5	98.89	10	98.16
	Mean	100.15	Mean	98.56	Mean	100.17	Mean	98.46
	%RSD	1.96	%RSD	0.539	%RSD	1.171	%RSD	0.59
Q-analysis	1	98.91	4	99.26	1	98.91	4	99.26
	1.5	98.65	6	100.19	1.5	98.92	6	100.71
	2	98.52	8	100.66	2	98.92	8	101.43
	2.5	100.49	10	99.73	2.5	99.86	10	100.24
	Mean	99.14	Mean	99.96	Mean	99.15	Mean	100.41
	%RSD	0.922	%RSD	0.601	%RSD	0.478	%RSD	0.904
Bivariate	1	99.01	4	99.42	1	99.08	4	98.19
	1.5	98.52	6	101.86	1.5	100.60	6	101.70
	2	99.81	8	101.21	2	100.49	8	101.82
	2.5	98.27	10	101.35	2.5	99.31	10	101.41
	Mean	98.90	Mean	100.96	Mean	99.87	Mean	100.78
	%RSD	0.680	%RSD	1.054	%RSD	0.788	%RSD	1.724